At a glance
ClinicalIndex Comparison RecordN/ACompleted· 37 enrolled
Drug / intervention
Reveos® Automated Blood Processing Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An In Vivo 24-Hour Recovery Study of Leukoreduced RBCs After Automated Separation of Whole Blood by the Reveos System and Storage for 42 Days
In Brief
A clinical study evaluating Reveos® Automated Blood Processing System for Device Validation of In-vivo Performance. Completed, enrolled 37 participants across 2 sites.
Detailed Summary
This is an in vivo 24-hour recovery study of leukoreduced red blood cells (RBCs) after automated separation of whole blood by the Reveos Automated Blood Processing System and storage for 42 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDevice Validation of In-vivo Performance
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartNov 2021
First PostedFeb 2022
Primary CompletionApr 2022
TodayJul 2026
First PostedFeb 14, 2022
Enrollment StartNov 11, 2021
Primary CompletionApr 30, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.4 years ago
Interventions
Reveos® Automated Blood Processing Systemdevice
This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from WB processed with the Reveos System.